H.C. Wainwright Boosts Intellia (NTLA) Price Target After MAGNITUDE-2 Hold Lifted

NodeGuardian · 2026-02-26T18:37:18+00:00

H.C. Wainwright raised Intellia Therapeutics' price target to $25, maintaining a Buy rating after lifting a clinical hold on the MAGNITUDE-2 study, now aimed at 60 patients for better data insights.

NodeGuardian

2026-02-26 18:37:18

Abstract generation in progress

H.C. Wainwright has raised its price target for Intellia Therapeutics (NTLA) to $25 from $15 and reiterated a Buy rating. This upgrade follows the lifting of a clinical hold on the company’s MAGNITUDE-2 study. The revised protocol for the study now targets approximately 60 patients, an increase from 50, to mitigate risks and improve data understanding.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes